Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

LillyDirect Foundayo vs MultiMedRx

LillyDirect Foundayo
Graded #174

Higher grade

vs+9.600000000000001
MultiMedRx
Graded #394

Lower grade

The verdict

LillyDirect Foundayo takes it — 67.2/100 to 57.6/100.

LillyDirect Foundayo grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLillyDirect Foundayo +27
72
45
Dose & formulationLillyDirect Foundayo +6
59
53
Clinical oversightMultiMedRx +1
78
79
Labs & monitoringMultiMedRx +1
52
53
FulfillmentLillyDirect Foundayo +13
80
67
Contract termsLillyDirect Foundayo +6
55
49
LillyDirect Foundayo · left barMultiMedRx · right bar

The numbers

MetricLillyDirect FoundayoMultiMedRx
WeighScore67.2/10057.6/100
GradeCC
Scorecard rank#174#394
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosedNot disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessYesYes
Oral / sublingualYesInjection only
LillyDirect Foundayo

Graded #174 · C

Strengths

  • Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
  • Direct from manufacturer — no compounding, no third-party reseller
  • Daily oral pill, no injections, no refrigeration
  • Available in all 50 states

Where it loses points

  • Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
  • Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
  • $25 savings card requires commercial insurance — Medicare and Medicaid not eligible
  • Strict empty-stomach 30-minute window may be hard for some patients to follow
MultiMedRx

Graded #394 · C

Strengths

  • Legal entity disclosed (MMRX MultiMedRx LLC) — uncommon transparency
  • Two physical addresses listed: Newport Beach, CA and Reno, NV
  • LegitScript seal present
  • Features brand-name GLP-1s (Ozempic, Wegovy, Zepbound) — rare in a mostly compounded-only field
  • Broader cardiometabolic menu (metformin, testosterone, HRT) alongside GLP-1

Where it loses points

  • No Mounjaro or Foundayo in the brand-name lineup (only Ozempic, Wegovy, Zepbound)
  • Monthly GLP-1 pricing isn't published — gated behind the consultation
  • $100 consultation fee adds friction; many peers bundle it into the medication price
  • Per-state availability not listed; only CA and NV offices disclosed
  • Whether compounded GLP-1 is offered isn't clear — verify during intake

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard